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Abstract
Objective To define the short- and mid-term outcomes of
patients discharged after an episode of acute-decompen-
sated heart failure (ADHF) and evaluate the differences
between patients discharged directly from the emergency
department (ED) and those discharged after hospitalization.
Methods We performed a prospective, multicenter, cohort-
designed study, including consecutive patients diagnosed
with ADHF in 27 Spanish EDs. Thirty-four variables on
epidemiology, comorbidity, baseline status, vital signs,
signs of congestion, laboratory tests, and treatment were
collected in every patient. The primary outcome was a
combined endpoint of ED revisit (without hospitalization)
or hospitalization due to ADHF, or all-cause death. Sec-
ondary outcomes were each of these three events individ-
ually. Outcomes were obtained by survival analysis at
different timepoints in the entire cohort, and crude and
adjusted comparisons were carried out between patients
discharged directly from the ED and after hospitalization.
Results Of the 3233 patients diagnosed with ADHF during
a 2-month period, we analyzed 2986 patients discharged
alive: 787 (26.4%) discharged from the ED and 2199
(73.6%) after hospitalization. The cumulative percentages
of events for the whole cohort (at 7/30/180 days) for the
combined endpoint were 7.8/24.7/57.8; for ED revisit 2.5/
9.4/25.5; for hospitalization 4.6/15.3/40.7; and for death
0.9/4.3/16.8. After adjustment for patient profile and cen-
ter, significant increases were found in the hazard ratios for
ED- compared to hospital-discharged patients in the com-
bined endpoint, ED revisit and hospitalization, being
higher at short-term [at 7 days, 2.373 (1.678–3.355), 2.069
(1.188–3.602), and 3.071 (1.915–4.922), respectively] than
at mid-term [at 180 days, 1.368 (1.160–1.614), 1.642
(1.265–2.132), and 1.302 (1.044–1.623), respectively]. No
significant differences were found in death.
Conclusions Patients with ADHF discharged from the ED
have worse outcomes, especially at short term, than those
discharged after hospitalization. The definition and
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implementation of effective strategies to improve patient
selection for direct ED discharge are needed.
Keywords Acute heart failure  Emergency department 
Disposition  Hospital admission  Outcome
Introduction
Acute-decompensated heart failure (ADHF) is one of the
most frequent diagnoses in patients who attend emergency
departments (EDs) worldwide, especially in Western
countries [1, 2]. In Spain, ADHF constitutes the leading
cause of medical hospitalization through EDs [3]. Despite
the substantial resource and economic implications of
hospitalization, the final decision of emergency physicians
to admit ADHF patients mainly relies on their subjective
and personal clinical experience rather than on objective-
supported evidence [4, 5]. This decision is complex and
challenging, as a wide spectrum of clinical presentations
ranging from minor forms of decompensation to life-
threatening illness can be observed in ADHF, and these are
often complicated by the presence of multiple co-morbid
conditions, psychosocial, socio-economic, self-care, and
health literacy issues [6]. As a result, some low-risk ADHF
patients are hospitalized by emergency physicians (in-
creasing the risk of hospital complications and health care
costs) and some high-risk patients are discharged from the
ED (enhancing the risk of clinical deterioration and death
shortly after leaving the ED) [7]. In this respect, several
groups have expressed concern about the potential harmful
effects of ED discharge on patient outcome [8–12]. How-
ever, it is not well known whether patients discharged from
the ED present increased adverse events compared to those
discharged from the hospital. The different risk profiles of
discharged and admitted patients, along with the con-
founding factors introduced by the hospitalization itself
make it difficult to directly compare these two groups.
Indeed, we only know of two previous studies assessing
this hypothesis, with contradictory results [8, 9]. In view of
these discrepancies, we designed the present study, the
primary aim of which was to compare the outcomes of
patients with an ADHF episode diagnosed in the ED
according to whether they were discharged directly from
the ED or after hospitalization.
Patients and methods
The IMPROV-ED study (Identifying areas of iMPROV-
ment at Emergency Department for patients with acute-
decompensated heart failure) is a prospective, multicenter,
cohort-designed study, including consecutive patients
diagnosed with ADHF in 27 Spanish EDs in both univer-
sity and community hospitals from all the regions of our
country. Patient inclusion was carried out from January 1st
to February 28th, 2014, following the EAHFE Registry
dynamics explained elsewhere [13, 14]. Briefly, patient
inclusion is consecutively performed by the attending
emergency physicians (all whom had received specific
instructions about the protocol during a meeting held the
week before the recruitment period), and all cases are
double checked by the principal investigator of each center
prior to the final patient inclusion into the database. The
diagnosis of AHF is made based on clinical criteria, since,
despite having some limitations, these are the criteria most
commonly used on clinical grounds [15]. Although natri-
uretic peptide values are not available in the EDs of 16 out
of the 27 participating centers, natriuretic peptide or
echocardiographic confirmation is carried out in the ED or
during hospitalization in more than 90% of patients fol-
lowing the ESC guidelines [16]. Interventions, treatments,
and patient allocation (admission or discharge) are entirely
based on the criteria of the attending emergency physician.
Subsequent follow-up through telephone contact and con-
sultation of medical reports is performed by the investi-
gators. The only exclusion criteria for the IMPROV-ED
study were: patients diagnosed with AHF during a
myocardial infarction with ST elevation (because most of
these patients are referred directly to angioplasty and do
not stay in the ED) and patients who died before being
discharged (because the main objective of the IMPROV-
ED study was to compare outcomes after discharge, and
therefore, patient had to be discharged to be included). The
protocol was approved by the Ethical Committees of all the
participating centers, and all patients gave informed con-
sent to be contacted for follow-up.
In every patient included in the IMPROV-ED study, we
collected the following 34 variables usually recorded in all
ADHF patients attending the ED: epidemiological data
(age and sex), comorbidities (hypertension, diabetes mel-
litus, dyslipemia, ischemic heart disease, heart valve dis-
ease, atrial fibrillation, chronic renal disease,
cerebrovascular disease, chronic obstructive pulmonary
disease, dementia, and previous episodes of ADHF),
baseline status (assessed by the NYHA class and Barthel
Index estimated 1 month prior to decompensation, and
echocardiography data—preserved or reduced systolic
function, left ventricular ejection fraction—if performed
during the index episode or in the previous 6 months), vital
signs [systolic blood pressure (SBP), heart rate and room-
air pulsioxymetry], clinical data of congestion at ED arrival
(legs oedema, increased jugular venous pressure, and
hepatomegaly), and results of blood tests (hemoglobin,
creatinine, sodium, and potassium) performed at ED, as
well as treatment at discharge [loop diuretics, thiazide
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diuretics, aldosterone-receptor blockers (ARB), angio-
tensin-converting-enzyme inhibitor (ACEI) or angiotensin-
II receptor antagonist (ARA-II), betablockers, and
digoxin].
The primary outcome of the IMPROV-ED study was a
combined endpoint, constituted by ED revisit due to heart
failure not requiring hospital admission, need for hospi-
talization due to heart failure, or all-cause death, whatever
occurred first. Secondary outcomes were each of these
three events considered individually: ED revisit (without
hospital admission), hospitalization, and death. We
defined the 7-, 30-, and 180-day outcomes for the whole
cohort of patients for every primary and secondary end-
points. The patients were divided into two groups
depending on whether they were discharged directly home
from the ED (without hospitalization) or after hospital-
ization to investigate possible differences in outcomes
between the two groups. In addition, a multivariable
analysis on the independent predictors of the primary
endpoint at 180 days was carried out separately for
patients directly discharged from ED and for patients
discharged after hospitalization.
The results are presented as mean and standard deviation
(SD) for the quantitative variables (or as median and per-
centile 25–75 (p25–75) for those without a normal distri-
bution and as absolute values and percentages for the
qualitative variables. Comparisons between groups were
made using the Student’s t test (or non-parametric Mann–
Whitney U test if not distributed normally) for quantitative
variables and the Chi-square test for qualitative variables.
Survival tables and curves for the primary and secondary
outcomes were obtained with the Kaplan–Meier method
for the entire cohort. Thereafter, we repeated the same
analysis for the two subgroups of patients (discharged from
ED and from hospital), and comparisons between the two
subgroups were performed using the log-rank test. Unad-
justed hazard ratios (HR) with a 95% confidence interval
(95% CI) were calculated for patients discharged from the
ED compared to those discharged from hospital and
adjusted for the differences found between the two groups.
Finally, a further HR adjustment by center was also per-
formed. All these calculations were repeated using survival
curves truncated at 7, 30, and 180 days. The independent
variables associated with the primary endpoint at 180 days
for each of the two groups (discharged from ED or after
hospitalization) were investigated separately by multivari-
able analysis using logistic regression. Sample size calcu-
lation was made to detect an absolute change of 6% in the
probability of presenting a combined endpoint at 180 days
in patients discharged from ED compared to those dis-
charged after hospitalization, for which a 60% of cumu-
lative event was estimated. Assuming an alpha error of
0.05 and a beta-error of 0.20, patients lost at follow-up of
2%, and a distribution of 25/75% of patients discharged
from ED/hospital, a sample size of 637/1931 patients was
determined for each respective group. Differences were
considered as statistically significant with a p value less
than 0.05, or when the 95% CI of the HR excluded the
value of 1. All calculations were performed using the SPSS
19.0 software and Epidat 3.1.
Results
Of 3233 patients diagnosed with AHF at 27 Spanish EDs
during the study period, we included 2986 patients dis-
charged alive and whose follow-up was available in the
final analysis (Fig. 1): 787 (26.3%) were discharged
directly from the ED [median ED stay: 0 (0–1) days;
median follow-up: 43 (5–61) days], and 2199 (73.6%) were
discharged after hospitalization [median ED stay: 7 (5–11)
days; median follow-up: 37 (24–55) days].
Table 1 presents the epidemiological and clinical data of
the patients studied. Patients were of advanced age [79.8
(10.0) years], predominantly women (55.1%), with several
comorbidities and some limitations in baseline status:
24.4% had NYHA class III–IV and 17.8% had severe or
complete dependence (Barthel index of 60 or less). Patients
discharged directly from the ED differed in 13 out of 34
variables compared to patients discharged after hospital-
ization: they were younger, had a lower frequency of
peripheral vascular disease, dementia and previous epi-
sodes of ADHF as comorbidities, were in a better baseline
functional status (either assessed by NYHA class or Barthel
Index), at ED arrival the heart rate was lower, pul-
sioxymetry higher, hemoglobin higher, and creatinine,
sodium and potassium values were lower, and, when dis-
charged, they were less frequently on treatment with ARB.
Among the entire cohort, 381 patients revisited the ED,
646 were hospitalized, and 196 died (65 died at home, with
no further ED revisit or hospitalization after the index
event discharge, Fig. 1). Survival curves for the primary
and secondary endpoints in the entire cohort are shown in
Fig. 2a. At 180 days, the combined endpoint was observed
in 57.8% of patients, with ED revisit, hospitalization and
death observed in 25.5, 40.7, and 16.8%, respectively.
When analyzed separately according to from where the
patient was discharged (Fig. 2b), we did not observe sig-
nificant differences in terms of the combined endpoint,
although patients discharged from the ED presented higher
ED revisits and a lower mortality rate, with no differences
in the need for hospitalization after discharge.
Table 2 shows the cumulative rates of 7-, 30-, and
180-day events for the whole cohort and the two sub-
groups. After adjustment of the HRs for differences
between patients discharged from the ED and after
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hospitalization, we found that both the combined endpoint,
ED revisit, and the need for hospitalization were signifi-
cantly more frequent in patients discharged from the ED.
Conversely, although death seemed to be less frequent in
patients discharged from the ED based on crude analysis,
this difference disappeared after adjustment (HR 0.813,
95% CI 0.504–1.312). Further adjustment by center
showed very similar results in all these outcomes; the risk
for the combined endpoint, ED revisit and need for hos-
pitalization but not death, remained increased in patients
discharged from the ED. On analysis of the HRs by time
intervals, the differences with respect to the null effect (HR
1) tended to decrease over time, being greater at the 7-day
analysis and the lowest at 180 days (Fig. 3).
We found that five variables were independently asso-
ciated with the combined endpoint at 180 days for patients
discharged directly from the ED: the presence of chronic
renal disease (p\ 0.05), ischemic heart disease (p\ 0.05)
and previous episodes of AHF (p\ 0.001) as comorbidi-
ties, a NYHA class III–IV at baseline (p\ 0.001) and SBP
at ED arrival (inverse relationship, p = 0.001). For patients
discharged after hospitalization, four independent variables
were associated with a combined endpoint at 180 days: the
presence of heart valve disease (p\ 0.01), chronic
obstructive pulmonary disease (p = 0.001) and previous
episodes of AHF as comorbidities (p\ 0.01), and a NYHA
class III–IV at baseline (p\ 0.01).
Discussion
The IMPROV-ED study shows that patients with ADHF
discharged from 27 different Spanish EDs present worse
outcomes than patients discharged after hospitalization,
even after adjustment for their different clinical profiles
and by center. This was observed when the outcome con-
sidered was ED revisit, need for hospitalization or the
combined endpoint, with the highest risk-frame time being
seen during the first 7 days when patients seem to be more
vulnerable to adverse outcomes. Conversely, the mortality
did not differ after ED discharge compared to hospital
discharge. Although we did not investigate the main causes
of these worse outcomes, our results suggest that the def-
inition and implementation of effective strategies are nee-
ded to improve patient selection for direct ED discharge
and eliminate this unacceptable increase in risk for patients
discharged directly from the ED without hospital
admission.
The results of the IMPROV-ED study are very similar to
those reported by Brar et al. [8]. They compared the same
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Fig. 1 Flowchart of patient inclusion
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Table 1 Characteristics of the patients included in the IMPROV-ED study
Total,
N = 2986
Discharged directly from the





Age (years) [mean (SD)] 79.8 (10.0) 78.6 (9.5) 80.2 (10.2) <0.001
Sex female [n (%)] 1634 (55.1) 427 (54.8) 1207 (55.2) 0.87
Comorbidity [n (%)]
Hypertension 2545 (85.3) 672 (85.6) 1873 (85.3) 0.86
Diabetes mellitus 1270 (42.6) 321 (40.9) 949 (43.2) 0.28
Dyslipidemia 1414 (47.4) 365 (46.5) 1049 (47.7) 0.57
Ischemic heart disease 915 (30.7) 256 (32.6) 659 (30.0) 0.19
Heart valve disease 844 (28.3) 223 (28.4) 621 (28.3) 0.98
Atrial fibrillation 1446 (48.5) 382 (48.7) 1064 (48.4) 0.94
Chronic renal disease (creatinine[2 mg/dL) 720 (24.2) 176 (22.4) 544 (24.8) 0.20
Cerebrovascular disease 372 (12.5) 84 (10.7) 288 (13.1) 0.09
Chronic obstructive pulmonary disease 779 (26.1) 200 (25.5) 579 (26.4) 0.66
Peripheral vascular disease 284 (9.5) 58 (7.4) 226 (10.3) <0.05
Dementia 386 (12.9) 67 (8.5) 319 (14.5) <0.001
Previous episodes of acute-decompensated heart
failure
1674 (56.3) 405 (51.7) 1269 (57.9) <0.01
Baseline status (30 days before decompensation)
NYHA class III–IV [n (%)] 620 (24.4) 119 (16.6) 501 (24.4) <0.001
Barthel index (points, from 0 to 100) [mean
(SD)]
82 (22) 87 (19) 80 (21) <0.001
Reduced LVEFa [n (%)] 580 (48.7) 145 (50.0) 435 (48.3) 0.65
LVEF (%, for patients with systolic dysfunction)
[mean (SD)]
38 (12) 39 (13) 37 (12) 0.13
Vitals at ED arrival [mean (SD)]
Systolic blood pressure at ED arrival (mmHg) 143 (27) 142 (25) 143 (27) 0.54
Heart rate at ED arrival (bpm) 88 (24) 84 (22) 89 (24) <0.001
Room-air pulsioxymetry (%) 92 (6) 95 (3) 92 (7) <0.001
Clinical data of congestion at ED arrival
Legs edema 2043 (68.5) 541 (68.8) 1502 (68.4) 0.87
Increased jugular venous pressure 603 (20.2) 145 (18.4) 458 (20.9) 0.16
Hepatomegaly 149 (5.0) 33 (4.2) 116 (5.3) 0.27
Laboratory data at ED
Hemoglobin at ED arrival (g/L) [mean (SD)] 121 (21) 123 (20) 120 (22) <0.01
Creatinine at ED arrival (mg/dL) [mean (SD)] 1.3 (9.9) 1.2 (0.8) 1.4 (0.9) <0.001
Sodium at ED arrival (mmol/L) [mean (SD)] 138 (5) 138 (4) 138 (5) 0.001
Potassium at ED arrival (mmol/L) [mean (SD)] 4.4 (0.7) 4.3 (0.6) 4.4 (0.7) <0.05
Treatment at discharge [n (%)]
Loop diuretics 2066 (73.2) 556 (73.6) 1510 (73.0) 0.78
Thiazide diuretics 350 (12.4) 103 (13.6) 247 (12.0) 0.26
Aldosterone-receptor blockers 605 (21.5) 134 (17.8) 471 (22.8) <0.01
ACEI or ARA-II 1528 (54.2) 414 (54.8) 1114 (53.9) 0.71
Betablockers 1215 (43.1) 308 (40.8) 907 (43.9) 0.15
Digoxin 412 (14.6) 117 (15.5) 295 (14.3) 0.46
Bold values refer the variables with a statistical significance between the two groups of the study
ED emergency department, LVEF left ventricular ejection fraction, ACEI angiotensin-converting-enzyme inhibitor, ARA-II angiotensin-II
receptor antagonist, SD standard deviation
a Available in 1191 (39.9%) patients
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composite outcome used in our study (death, hospitaliza-
tion, and ED visit) over a 30-day period and found higher
rates for patients discharged directly from the ED (30.2,
35.3, and 44.9% for high-, medium-, and low-volume EDs)
compared to patients discharged after hospital admission
(23.5, 30.1, and 37.5%, respectively). Interestingly, these
differences diminished over time on evaluating outcomes
at 90 days, being very similar to what we observed.
However, the two studies had two methodological
differences. Brar et al. considered all-cause ED revisit or
hospitalization, while we only considered those due to
heart failure. This could explain the higher rates reported in
the study by Brar et al. compared to ours (23.8% for hos-
pital discharge and 27.2% for ED discharge). In addition,
they considered the index event (i.e., ED attendance) as the
starting point for the follow-up period. This could have led
to an overestimation of the differences between ED and
hospital discharge reported by these authors, since ED
Fig. 2 Survival curves for
primary and secondary
outcomes for the whole cohort
(a) and for the subgroups of
patients discharged from the
emergency department and after
hospitalization (b)
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reconsultation and rehospitalization is not possible during
the time of hospitalization in patients discharged from the
hospital. Accordingly, it could be argued that the better
outcomes of patients discharged from hospital observed by
the Brar group were spurious due to this fact, while these
doubts are eliminated by our results, because the starting
point was patient discharge. The design of our study makes
comparisons more reasonable, because, regardless of
whether patients are discharged from the ED or the hos-
pital, discharge decisions are made when physicians are







N = 787 (%)
Discharged after
hospitalization,
N = 2199 (%)
Unadjusted HR
(95% CI) for direct
ED discharge
Adjusteda HR (95%
CI) for direct ED
discharge
Adjustedb HR (95%
CI) for direct ED
discharge
Combined endpoint
At 7 days 7.8 11.5 6.4 1.847 (1.417–2.407) 2476 (1.758–3.488) 2.373 (1.678–3.355)
At 30 days 24.7 27.2 23.8 1.197 (1.019–1.406) 1.504 (1.230–1.838) 1.448 (1.183–1.773)
At 180 days 57.8 57.8 57.7 1.125 (0.987–1.282) 1.400 (1.118–1.651) 1.368 (1.160–1.674)
ED revisit (without hospitalization)
At 7 days 2.5 4.3 1.9 2.247 (1.415–3.568) 2.035 (1.175–3.523) 2.069 (1.188–3.602)
At 30 days 9.4 13.0 8.2 1.668 (1.288–2.160) 1.758 (1.284–2.406) 1.741 (1.269–2.389)
At 180 days 25.5 32.2 21.4 1.493 (1.210–1.842) 1.626 (1.254–2.109) 1.642 (1.265–2.132)
Hospitalization
At 7 days 4.6 7.1 4.7 1.960 (1.387–2.771) 3.399 (2.130–5.424) 3.071 (1.915–4.922)
At 30 days 15.3 15.9 15.0 1.097 (0.885–1.358) 1.479 (1.129–1–936) 1.393 (1.062–1.825)
At 180 days 40.7 36.7 42.6 1.026 (0.863–1.220) 1.364 (1.094–1.701) 1.302 (1.044–1.623)
Death
At 7 days 0.9 0.8 1.0 0.660 (0.329–2.021) 0.327 (0.041–2.597) 0.333 (0.041–2.695)
At 30 days 4.3 2.3 5.0 0.440 (0.256–0.758) 0.408 (0.173–0.960) 0.431 (0.182–1.019)
At 180 days 16.8 11.2 19.9 0.608 (0.424–0.872) 0.813 (0.504–1.312) 0.818 (0.506–1.324)
ED emergency department
a Adjusted for 13 variables: age, peripheral vascular disease, dementia, previous episodes of acute-decompensated heart failure, NYHA class,
Barthel index, heart rate, room-air pulsioxymetry, hemoglobin, creatinine, sodium, potassium and treatment with aldosterone-receptor blocker
b Adjusted for the above-mentioned 13 variables and by center

















Hazard ratio (95% CI)
For ADHF patients discharged from emergency department 
(respect to discharged after hospitlization)
Worse outcomeBetter outcome
Fig. 3 Representation of the
hazard ratios (HR) with 95%
confidence interval (CI) of
patients with acute-
decompensated heart failure
(ADHF) discharged from the
emergency department
compared to those discharged
after hospitalization, after
adjustment for the 13 variables
for which they were different
(age, peripheral vascular
disease, dementia, previous
episodes of ADHF, NYHA
class, Barthel index, heart rate,
room-air pulsioxymetry,
hemoglobin, creatinine, sodium,
potassium, and treatment with
aldosterone-receptor blocker)
and by center
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sure that patients are well enough to return home and
patients in both groups are in a similar situation in terms of
clinical stability.
The results of the present study and those by Brar et al.
are in contrast with others published by Lee et al. [9], who
reported that short-term mortality (the sole endpoint eval-
uated by this group) was very similar on comparing
patients discharged from the ED versus those discharged
after hospital admission (with comparable predicted risks
of 7- and 30-day death) but divergent thereafter, with
patients discharged from the ED showing a worse outcome.
Since the most plausible cause for this mid-term increase
(at 100 days) in mortality lays mainly in ambulatory fol-
low-up rather than in the ED or hospital decision of dis-
charge itself, a potential explanation may be some defects
in follow-up arrangements when patients are discharged
directly from ED. We found no differences in terms of
mortality and, in fact, we found a non significant decrease
in mortality in patients discharged from the ED compared
to those discharged after hospitalization. Moreover, the HR
tended to shift towards the null effect over time (HR of 1).
Therefore, although the decision of direct ED discharge has
a negative impact on ED revisit, hospitalization, or com-
bined event risks, we can conclude that ED discharge of
patients with ADHF has no negative effect on mortality.
Ideally, outcomes should be better for patients dis-
charged from the ED, as emergency physicians are more
likely to reserve this approach for patients at lowest risk.
The paradoxical finding of higher ED revisits and hospi-
talization risk among patients discharged from the ED
found in the present study, especially short term after ED
discharge, highlights the need for robust risk-stratification
instruments and structured discharge planning. Although
we have tried to equate the patient risk profile with
adjustment of patient differences, we did not assess patient
interactions with health care resources and health care
giver interventions during follow-up. Therefore, follow-up
arrangements after hospital discharge may have been better
than those made after ED discharge, and could account, at
least in part, for these differences. Failure to initiate
guideline-directed medical therapy and the lack of timely,
outpatient follow-up post-discharge are two variables that
repeatedly appear to be particularly important in the
determination of patient outcome [17–19]. Alternatively to
poorer ED management, increased ED revisit by patients
discharged from the ED could be due, at least to some
extent, by some patients possibly using the ED as a sub-
stitute for primary care physicians either because they
believe they receive better service, or because they are ill-
educated. Therefore, it is clear that, although not directly
investigated in the present study, patient psychology plays
an important role in the patient choice to go to the ED
rather than primary care for mild decompensations.
Our findings have several different repercussions. Inad-
equate patient discharge, regardless of whether it is done
from the ED or after hospitalization, could be one of the
main reasons for the lack of improvement in the prognosis of
patients with ADHF over the last decades [20, 21]. In
addition, an analysis based on a representative sample of ED
visits between 2002 and 2010 in the United States found no
change in the number of ED visits for ADHF or in the rate of
hospitalization following ED visits [22]. Indeed, specific
guidelines for ADHF management have only very recently
become available, being focused more on the diagnosis and
treatment of ADHF rather than on decision-making related
to patient disposition [16, 19, 23–25]. Several recent expert
consensuses have raised this pitfall and have recommended
the development of specific tools to stratify patient risk to
better detect high-risk patients for prompt aggressive treat-
ment and proper hospital allocation, as well as better identify
low-risk patients for safe ED discharge [26–29]. It is
important to note that predictive factors for bad outcomes
can differ for patient discharged from ED and after hospi-
talization [5–10, 30, 31]. As shown in the IMPROV-ED
study, two risk factors were common in both groups of
patients (previous episodes of ADHF and NYHA class III–
IV at baseline), but chronic renal disease, ischemic heart
disease, and SBP at ED arrival were specific for patients
directly discharged from ED. Therefore, this should be taken
into account when developing specific scales to guide
patient discharge. In addition, such predictive instruments
that identify patients who can safely be discharged from the
ED while simultaneously addressing barriers against suc-
cessful outpatient management could have a potentially
significant impact on quality of life and resource expendi-
tures [28]. In addition, in the US, the cost of unplanned
hospital readmissions to Medicare in 2004 was estimated to
be 17.4 billion USD [1], and the Centers for Medicare and
Medicaid Services reduced payments to inpatient prospec-
tive payment system hospitals with excess readmissions in
2012 [32]. Understandably, there is enormous economic
interest in detecting areas of improvement and designing
interventions to mitigate hospital readmissions, and ADHF
is one of the leading causes of ED and hospital readmissions
[33, 34]. In this sense, the short-stay units of hospitalization,
an organizational option in halfway between direct dis-
charge and hospitalization in a regular ward, have proved to
save days of hospitalization in patients with ADHF while
not affecting clinically relevant outcomes [35].
The IMPROV-ED study has some limitations. First, the
Spanish EDs participating in the study were not randomly
selected. Second, Spain has a public health care system,
and all the EDs corresponded to this public network. This
could influence patient management, especially in regard to
trends in admission and readmission dynamics, which
could differ from those observed in countries with a mainly
376 Clin Res Cardiol (2017) 106:369–378
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private health care system. Third, it would have been of
interest to know how the decision-making of the emer-
gency physicians of either sending patients home or
admitting them to the hospital was carried out to, but we
did not ask them about this specific issue and current
guidelines do not include specific recommendations on this
aspect. Fourth, patients who died during hospital admission
were excluded from this study. However, patients who
were sent home from the ED, but died a few days later
were not excluded. Although this could be considered a
bias, it should be noted that time 0 was set at the time of
patient discharge, when the doctor (emergency physician or
another hospital specialist) considered that the patient was
ready to be discharged, as our main objective was to know
if decisions taken by emergency physicians put patients at
increased risk of adverse events. Fifth, we did not assess
the medical or social interventions given to patients after
ED or hospital discharge, but rather we evaluated the
presence of primary or secondary endpoints. For example,
some patients were discharged without loop diuretics.
Although the most frequent reasons were because patients
were treated with antihypertensive drugs that contained
thiazides and for some patients volume overload was
minimal, we did not check if loop diuretic were added in
the ambulatory after discharge. Sixth, we estimated the
sample size for the primary outcome (combined endpoint)
at 180 days. Consequently, some estimations made for
other outcomes and at other time-points (especially at
7 days when the number of events is more limited) could
include a beta-error. Despite these limitations, we believe
our data demonstrate that, even though direct ED discharge
of patients with ADHF is not associated with a greater
mortality, it implies an increased risk of later ED revisit,
hospitalization, or combined events, especially during the
more vulnerable period within the first 7 days after dis-
charge. It is, therefore, crucial to develop and implement
measures to counteract this increased risk.
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5. Miró O, Llorens P, Martı́n-Sánchez FJ, Herrero P, Jacob J, Pérez-
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